These challenges were addressed by 1) creating representations of contact sites and establishing the ability to visualize subsets of synaptic sites; 2) enabling synchronous visualization of neuron ...

We look forward to sharing for rosnilimab, a depleter and agonist targeting PD-1+ T cells, top-line Phase 2b rheumatoid arthritis data in February 2025 and top-line Phase 2 ulcerative colitis data ...